Publications

Efficacy and Safety by Race and Ethnicity in a Randomized, Double-Blind, Vehicle-Controlled, Phase 2a Study Evaluating Once-Daily Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis

Pooled Efficacy and Safety Results from the DERMIS-1 and DERMIS-2 Phase 3 Trials of Once-Daily Roflumilast Cream 0.3% for Treatment of Chronic Plaque Psoriasis

Pooled Efficacy and Safety Results from the DERMIS-1 and DERMIS-2 Phase 3 Trials of Once-Daily Roflumilast Cream 0.3% by Baseline Body Surface Area

Efficacy and Safety of Once-Daily Roflumilast Cream 0.3% in Patients with Knee/Elbow Involvement: Pooled Results from Phase 3 Trials (DERMIS-1 and DERMIS-2)

Long-Term Safety and Efficacy of Roflumilast Cream 0.3% in Patients with Chronic Plaque Psoriasis: Interim Results from a 24-Week, Phase 3 Open-Label Study

Effects of Roflumilast Cream on Patient Burden and Work Productivity in Patients with Psoriasis

Efficacy and Tolerability of Roflumilast Cream 0.3% in Patients with Chronic Plaque Psoriasis Involvement on the Face, Intertriginous, or Genital Areas: Pooled Results from Phase 3 Trials (DERMIS-1 and DERMIS-2)

Long-Term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis in a 24–52-Week, Open-Label Phase 2 Trial

Efficacy and Safety of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis in a Phase 3 Trial